News
Vas Narasimhan said on Tuesday that if the U.S. adopts international drug pricing, all companies would have to “relook at ...
Novartis has a lot cooking with new drug launches, and the company is not letting potential U.S. tariffs on pharmaceuticals ...
Novartis raises 2025 sales and profit forecast as key drugs drive strong Q1 results; core operating income up 23% to $5.6 ...
Novartis has done a little spring cleaning, sweeping a phase 2 osteoarthritis prospect and first-in-human radioconjugate out of its pipeline after assessing evidence on the programs. | Novartis has ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
The chief executive of generic drugmaker Sandoz said a proposal by the CEOs of Novartis and Sanofi to introduce a Europe-wide ...
FDA granted an accelerated approval for Vanrafia for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. Vanrafia can be ...
Novartis hat die Prognose für das Gesamtjahr angehoben, nachdem der Gewinn im ersten Quartal vor allem dank Medikamenten ...
European drugmakers are urging the EU to allow higher medicine prices, warning that without stronger investment incentives, ...
15hon MSN
Vasant Narasimhan, Novartis CEO, joins 'Money Movers' to discuss the company's quarterly earnings results. Amazon listing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback